• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

不同类型肺动脉高压的肺动脉顺应性。

Pulmonary artery compliance in different forms of pulmonary hypertension.

机构信息

Comprehensive Pulmonary Hypertension Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.

Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Denver, Colorado, USA.

出版信息

Heart. 2023 Jun 26;109(14):1098-1105. doi: 10.1136/heartjnl-2022-321760.

DOI:10.1136/heartjnl-2022-321760
PMID:36787969
Abstract

OBJECTIVE

Pulmonary artery compliance (PAC), estimated as stroke volume (SV) divided by pulmonary artery pulse pressure (PP), may be a predictor of survival in pulmonary arterial hypertension (PAH). Resistance-compliance (RC) time, the product of PAC and pulmonary vascular resistance, is reported to be a physiological constant. We investigated if differences in PAC and RC time exist between pulmonary hypertension (PH) subgroups and examined whether PAC is an independent predictor of transplant-free survival in PAH.

METHODS

This was a retrospective analysis of adult PAH (n=532) and chronic thromboembolic PH (CTEPH, n=84) patients enrolled in the US Pulmonary Hypertension Association Registry from 2015 to 2019. PAC and RC time were compared between PH subgroups (connective tissue disease-PAH (CTD-PAH), idiopathic/heritable-PAH (i/h-PAH), drug/toxin-PAH (d/t-PAH)). Cox proportional hazards models were constructed for transplant-free survival, adjusting for REVEAL 2.0 risk score.

RESULTS

There were no differences in estimated PAC between PAH subgroups, nor between PAH and CTEPH. RC time was shorter in CTEPH compared with PAH (median 0.55 (IQR 0.45-0.64) vs 0.62 (0.52-0.73) s, p<0.0001). RC time was shortest in CTD-PAH when compared with i/h-PAH and d/t-PAH ((0.59±0.18) vs (0.65±0.20) vs (0.73±0.25) s, p=0.0001). PAC was associated with transplant-free survival (HR 0.72, 95% CI 0.55 to 0.94, p=0.02) but was not an independent predictor of outcome after adjustment for REVEAL 2.0 score.

CONCLUSION

PAC was similar between PH groups and was not an independent predictor of transplant-free survival in PAH. RC time was different between PH subgroups, challenging RC time constancy.

TRIAL REGISTRATION NUMBER

NCT04071327.

摘要

目的

肺动脉顺应性(PAC)可通过每搏量(SV)除以肺动脉脉搏压(PP)来估计,可能是肺动脉高压(PAH)患者生存的预测指标。阻力顺应性(RC)时间是 PAC 与肺血管阻力的乘积,据报道为生理常数。我们研究了 PH 亚组之间是否存在 PAC 和 RC 时间的差异,并检查了 PAC 是否是 PAH 无移植生存的独立预测因素。

方法

这是对 2015 年至 2019 年期间在美国肺动脉高压协会登记处登记的成年 PAH(n=532)和慢性血栓栓塞性 PH(CTEPH,n=84)患者进行的回顾性分析。比较了 PH 亚组(结缔组织疾病相关-PAH(CTD-PAH)、特发性/遗传性-PAH(i/h-PAH)、药物/毒素相关-PAH(d/t-PAH)之间的 PAC 和 RC 时间。构建了无移植生存的 Cox 比例风险模型,调整了 REVEAL 2.0 风险评分。

结果

PAH 亚组之间以及 PAH 与 CTEPH 之间的估计 PAC 无差异。与 PAH 相比,RC 时间在 CTEPH 中较短(中位数 0.55(IQR 0.45-0.64)与 0.62(0.52-0.73)s,p<0.0001)。与 i/h-PAH 和 d/t-PAH 相比,CTD-PAH 时 RC 时间最短((0.59±0.18)与(0.65±0.20)与(0.73±0.25)s,p=0.0001)。PAC 与无移植生存相关(HR 0.72,95%CI 0.55 至 0.94,p=0.02),但在调整 REVEAL 2.0 评分后,PAC 不是无移植生存的独立预测因素。

结论

PAH 组之间的 PAC 相似,并且不是 PAH 无移植生存的独立预测因素。RC 时间在 PH 亚组之间不同,这对 RC 时间的恒定性提出了挑战。

试验注册号

NCT04071327。

相似文献

1
Pulmonary artery compliance in different forms of pulmonary hypertension.不同类型肺动脉高压的肺动脉顺应性。
Heart. 2023 Jun 26;109(14):1098-1105. doi: 10.1136/heartjnl-2022-321760.
2
The difference of gas exchange pulmonary arterial capacitance with postural change between chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension.慢性血栓栓塞性肺动脉高压与肺动脉高压之间气体交换性肺血管容量随体位变化的差异。
J Cardiol. 2025 Jul;86(1):97-99. doi: 10.1016/j.jjcc.2025.04.003. Epub 2025 Apr 18.
3
Guanylate cyclase stimulators for pulmonary hypertension.用于肺动脉高压的鸟苷酸环化酶刺激剂。
Cochrane Database Syst Rev. 2016 Aug 2;2016(8):CD011205. doi: 10.1002/14651858.CD011205.pub2.
4
Macitentan and Tadalafil Combination Therapy in Patients with Pulmonary Arterial Hypertension and Cardiovascular Comorbidities: Real-World Evidence from OPUS and OrPHeUS.马昔腾坦与他达拉非联合治疗肺动脉高压合并心血管疾病患者:来自OPUS和OrPHeUS的真实世界证据
Adv Ther. 2025 May 19. doi: 10.1007/s12325-025-03180-0.
5
Sleep-Related Hypoxia, Right Ventricular Dysfunction, and Survival in Patients With Group 1 Pulmonary Arterial Hypertension.睡眠相关低氧、右心室功能障碍与 1 型肺动脉高压患者的生存
J Am Coll Cardiol. 2023 Nov 21;82(21):1989-2005. doi: 10.1016/j.jacc.2023.09.806.
6
Sex as a prognostic factor for mortality in adults with acute symptomatic pulmonary embolism.性别作为急性症状性肺栓塞成年患者死亡率的一个预后因素。
Cochrane Database Syst Rev. 2025 Mar 20;3(3):CD013835. doi: 10.1002/14651858.CD013835.pub2.
7
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
8
Antioxidants for male subfertility.用于男性生育力低下的抗氧化剂。
Cochrane Database Syst Rev. 2014(12):CD007411. doi: 10.1002/14651858.CD007411.pub3. Epub 2014 Dec 15.
9
Positioning for acute respiratory distress in hospitalised infants and children.急性呼吸窘迫患儿的体位摆放。
Cochrane Database Syst Rev. 2022 Jun 6;6(6):CD003645. doi: 10.1002/14651858.CD003645.pub4.
10
Sex and gender as predictors for allograft and patient-relevant outcomes after kidney transplantation.性别作为肾移植后同种异体移植及患者相关预后的预测因素。
Cochrane Database Syst Rev. 2024 Dec 19;12(12):CD014966. doi: 10.1002/14651858.CD014966.pub2.

引用本文的文献

1
Reduced pulmonary arterial compliance predicts poor short-term outcome in children with pulmonary arterial hypertension independent of pulmonary vascular resistance.肺动脉顺应性降低预示着肺动脉高压患儿短期预后不良,且与肺血管阻力无关。
Front Cardiovasc Med. 2025 May 22;12:1526435. doi: 10.3389/fcvm.2025.1526435. eCollection 2025.
2
Precision Medicine for Pulmonary Vascular Disease: The Future Is Now (2023 Grover Conference Series).肺血管疾病的精准医学:未来已来(2023年格罗弗会议系列)
Pulm Circ. 2025 Jan 2;15(1):e70027. doi: 10.1002/pul2.70027. eCollection 2025 Jan.
3
Defining Echocardiographic Degrees of Right Heart Size and Function in Pulmonary Vascular Disease from the PVDOMICS Study.
从PVDOMICS研究中定义肺血管疾病中右心大小和功能的超声心动图分级
Circ Cardiovasc Imaging. 2024 Oct;17(10). doi: 10.1161/circimaging.124.017074. Epub 2024 Oct 15.
4
Relationship of TAPSE Normalized by Right Ventricular Area With Pulmonary Compliance, Exercise Capacity, and Clinical Outcomes.经右心室面积校正的 TAPSE 与肺顺应性、运动能力和临床结局的关系。
Circ Heart Fail. 2024 May;17(5):e010826. doi: 10.1161/CIRCHEARTFAILURE.123.010826. Epub 2024 May 6.
5
Sildenafil Versus Placebo for Early Pulmonary Vascular Disease in Scleroderma (SEPVADIS): protocol for a randomized controlled trial.硬皮病肺血管早期病变(SEPVADIS)患者应用西地那非与安慰剂的随机对照试验研究方案
BMC Pulm Med. 2024 Apr 30;24(1):211. doi: 10.1186/s12890-024-02892-3.
6
Investigating the "sex paradox" in pulmonary arterial hypertension: Results from the Pulmonary Hypertension Association Registry (PHAR).研究肺动脉高压中的“性别悖论”:来自肺动脉高压协会注册中心(PHAR)的结果。
J Heart Lung Transplant. 2024 Jun;43(6):901-910. doi: 10.1016/j.healun.2024.02.004. Epub 2024 Feb 13.
7
Nebulisation of Paclitaxel, Sotatercept and Iloprost for pulmonary hypertension for lung cancer. From to .用于肺癌所致肺动脉高压的紫杉醇、索他洛尔和伊洛前列素雾化吸入。从……到……
J Cancer. 2024 Jan 1;15(4):871-879. doi: 10.7150/jca.90732. eCollection 2024.
8
Distensibility, an Early Disease Marker of Pulmonary Vascular Health: Ready for Clinical Application.可扩张性,一种肺血管健康的早期疾病标志物:准备好用于临床应用。
J Am Heart Assoc. 2023 Oct 17;12(20):e031605. doi: 10.1161/JAHA.123.031605. Epub 2023 Oct 10.
9
Inhibition of pulmonary artery smooth muscle cells via the delivery of curcuminoid WZ35 by Cu-based metal organic frameworks.通过铜基金属有机框架传递姜黄素 WZ35 抑制肺动脉平滑肌细胞。
IET Nanobiotechnol. 2023 Jul;17(5):420-424. doi: 10.1049/nbt2.12138. Epub 2023 May 16.